Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-03 @ 8:15 AM
Study NCT ID:
NCT03722420
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-28
First Post:
2018-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015466', 'term': 'Leukemia, Myeloid, Chronic-Phase'}], 'ancestors': [{'id': 'D015464', 'term': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive'}, {'id': 'D007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009196', 'term': 'Myeloproliferative Disorders'}, {'id': 'D001855', 'term': 'Bone Marrow Diseases'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000606751', 'term': '4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide'}, {'id': 'D000068877', 'term': 'Imatinib Mesylate'}], 'ancestors': [{'id': 'D001549', 'term': 'Benzamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001565', 'term': 'Benzoates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011743', 'term': 'Pyrimidines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Parallel, 2 arms'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 238}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2018-12-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-10-24', 'studyFirstSubmitDate': '2018-10-25', 'studyFirstSubmitQcDate': '2018-10-25', 'lastUpdatePostDateStruct': {'date': '2024-10-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-10-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-03-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The MMR rate', 'timeFrame': 'at 12 months after radotinib or imatinib treatment', 'description': 'The MMR rate at 12 months after radotinib or imatinib treatment in patients with newly diagnosed CML-CP.'}], 'secondaryOutcomes': [{'measure': 'MMR rate', 'timeFrame': 'by 3, 6, 9, and 12 months of treatment.', 'description': 'To compare MMR rate for the best response in patients within specific periods.'}, {'measure': 'Complete Cytogenetic Response(CCyR) rate', 'timeFrame': 'by 3, 6, 9, and 12 months of treatment.', 'description': 'To compare CCyR rate for the best response in patients within specific periods.'}, {'measure': 'The MR 4.0 and MR 4.5 rates', 'timeFrame': 'by 3, 6, 9, and 12 months of treatment, and late', 'description': 'To compare the MR4.0 and MR4.5 rates for the best response in patients within specific periods.'}, {'measure': 'Disease progression (AP/BC) rate', 'timeFrame': 'at 3, 6, and 12 months', 'description': 'To compare disease progression for the best response in patients within specific periods.'}, {'measure': 'Failure rate according to European Leukemia Net (ELN) guideline 2013 (ELN 2013*)', 'timeFrame': 'at 3, 6, and 12 months', 'description': 'To compare failure rate for the best response in patients within specific periods.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Chronic Myeloid Leukemia, Chronic Phase']}, 'descriptionModule': {'briefSummary': 'This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD).\n\nThis study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).', 'detailedDescription': 'Patients randomized to the radotinib arms will receive 300 mg of radotinib BID at approximately 12-hour intervals. Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.\n\nThe primary efficacy endpoint is the rate of Major Molecular Response(MMR) at 12 months (1 month = 4 weeks = 28 days), defined as BCR ABL1/ABL% ≤ 0.1% by international scale. The Molecular Response(MR) rate will be measured every 3 months by Real-time Quantitative(RQ)-Polymerase Chain Reaction(PCR) in a central laboratory. All patients will be treated and/or followed for 12 months (48 weeks) after randomization.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. China who are 18 years of age or older.\n2. Eastern cooperative oncology group (ECOG) score 0, 1, or 2.\n3. Patients with confirmed diagnosis of CML-CP within last 6 months.\n4. Patients with cytogenetically confirmed Ph+ CML in chronic phase\n5. Patients with typical BCR-ABL1 transcript type such as b2a2 and b3a2.\n6. Patients with adequate organ function.\n7. Women of childbearing potential should have negative serum or urine pregnancy test within 14 days before study entry.\n8. Patients providing written informed consent before initiation of any study-related activities.\n\nExclusion Criteria:\n\n1. Patients with Philadelphia chromosome negative but BCR-ABL1 positive CML.\n2. Patients who had been treated with interferon or other targeted anti-cancer therapy which inhibits the growth of leukemic cells\n3. Concurrently clinically significant primary malignancy\n4. Patients who previously received radiotherapy\n5. Patients with impaired cardiac function.\n6. uncontrolled chronic medical condition'}, 'identificationModule': {'nctId': 'NCT03722420', 'briefTitle': 'Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Il-Yang Pharm. Co., Ltd.'}, 'officialTitle': 'A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase', 'orgStudyIdInfo': {'id': 'RT51CN03'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Radotinib 300mg', 'description': 'Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months', 'interventionNames': ['Drug: Radotinib']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Imatinib 400mg', 'description': 'Oral administration of Imatinib 400mg QD (400mg/day) for 12months', 'interventionNames': ['Drug: Imatinib']}], 'interventions': [{'name': 'Radotinib', 'type': 'DRUG', 'otherNames': ['Supect'], 'description': 'Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).', 'armGroupLabels': ['Radotinib 300mg']}, {'name': 'Imatinib', 'type': 'DRUG', 'otherNames': ['Glivec'], 'description': 'Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.', 'armGroupLabels': ['Imatinib 400mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100044', 'city': 'Beijing', 'country': 'China', 'facility': "Peking University People's Hospital(北京大学人民医院)", 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}], 'overallOfficials': [{'name': 'Jiang Qian', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Peking University People's Hospital(北京大学人民医院)"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Il-Yang Pharm. Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}